“The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide whether they had HRR gene alterations. In this ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris ...

The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...

Over the last 50 years, research funded by the National Institutes of Health (NIH) and National Cancer Institute (NCI) has played a role in every major advancement related to cancer prevention, ...

Recruiting and developing oncology practice staff takes care and strategy. ASCO can be a unique resource as you search for ideal candidates and work to bolster the expertise and efficiency of your ...

The Resilience Skills Training Program aims to improve physician wellness in oncology through a proactive approach. The program targets current trainees to help create a culture change surrounding ...

Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18 F-FDG PET/CT and clinical factors for metastatic colorectal ...

To learn more about the Oncology Medical Home standards and ASCO Certified recognition from ASCO, please click the button below and submit your questions. ASCO Certified has launched a new application ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...